Medical Developments International Limited · ASX:MVP
Medical Developments International — Investor Presentation (May 2005)
11 slides from Medical Developments International's investor presentation, May 25, 2005
Slide 1: Medical Developments International Limited Presentation
Medical Developments International Limited (“MDI’) Presentation Sydney — 25 May 2005
Slide 2: Introduction — MDI Profile
© S es x S Boos: 2 2 g Z e a S a £ S w G & & = o = Introduction — MDI Profile (4) Product Segments + Pharmaceutical - Single product (Penthrox™ — inhaled analgesic) - Only manufacturer in the world - TGA & Medsafe (NZ) - Plant is GMP certified - 53% of sales - Currently used in ambulance, military,
Slide 3: Organic growth is expected in established markets during FY06
© S es x S Boos: 2 2 g Z e a S a £ S w G & & = o = Growth Strategy — Penthrox Organic growth is expected in established markets during FY06 5 Applications/Uses New Current Methoxyflurane Growth Strategy Rescue Services Military Ambulance Research Institutions New Zealand Dubai Police Research Instit
Slide 4: Growth prospects in new applications in Australia, particularly dentistry
© S es x S Boos: 2 2 g Z e a S a £ S w G & & = o = Growth Strategy — Penthrox (Domestic) There are exciting growth prospects in new applications in Australia in FY06, (4) particularly in dentistry Applications/Uses New Current Methoxyflurane Growth Strategy Dentists (Australia & New Zealand) = Hospi
Slide 5: Penthrox addresses the major issues in dentistry: pain and anxiety management
Growth Strategy — Penthrox (Domestic) €3 Penthrox™ addresses the major issues in dentistry: pain and anxiety management oO Ze 2 Examples of Use Trial Results* pin, AS 5 + Administration of local anaesthetic Question Positive Response ce + Initial examination of patients in pain Nervousness decreased
Slide 6: International growth in FY06 in new markets where registration obtained
Growth Strategy — Penthrox (International) (a) International growth in FY06 could be exciting in new markets where registratio obtained Methoxyflurane Growth Strategy oO 6 Market > 200 mill I . + Market > million people iar Dentists + Distributors appointed S + Marketing & sales material Ss dissemin
Slide 7: Operational Capacity
Operational Capacity There is sufficient manufacturing capacity to meet prospective demand in FY2006 * Manufacturing Infrastructure * Capacity sufficient to meet prospective demand in 2006 «Capex of $120k to install capacity for further growth * “Greenfields” plant in preliminary design phase » Huma
Slide 8: Growth Strategy — Medical Devices
Growth Strategy — Medical Devices GS In FYO6, growth should be moderate. The focus will be on optimising the value of existing distribution arrangements together with making select new appointments Current Distribution Arrangements (to be leveraged) United Kingdom Iraq Taiwan Australia Saudi Arabia
Slide 9: MDI Financial Profile
MDI Financial Profile €3 MDI is profitable despite making significant investments in growth Key Financials {as at 31 December 2004) $000 Revenue 2850 EBITDA 555 NPAT 117 Key Investments in Growth (6 months to 31 December 2004) © S es x S Boos: 2 2 g Z e a S a £ S w G & & = o = $000 Registrations* 37
Slide 10: FY05 Prognosis
FYO5 Prognosis jf \) Sales will exceed FY04 sales (annualised) but are unlikely to meet forecast cF due to lower than forecast sales in Medical Devices Product Comment Penthrox™ Ambulance growth in line with forecast Expect orders from Pakistan Military, UAE Military & Oz Dentistry NZ Ambulance take
Slide 11: Closing Comments
Closing Comments + Base of existing revenue, cashflow and profits + Penthrox™ will be the growth engine in FY2006 with significant sales likely in Dentistry, the Middle East and Asia + Penthrox™ sales in hospitals and GP’s will grow more slowly + Moderate growth is expected in medical devices in FY2
Medical Developments International — Investor Presentation (May 2005) on 6ix